MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'

MDxHealth SA (NASDAQ:MDXH) stock skyrocketed on Friday after the diagnostic company reported mixed quarterly earnings.

The company reported a second-quarter loss of 18 cents, missing the consensus loss of 16 cents.

MDxHealth Reports Mixed Test Volume Results

Sales rose 16% year over year to $27.20 million, beating the consensus of $25.884 million.

Tissue-based (Confirm mdx and GPS mdx) test volume was 12,525, a decrease of 1% over the prior-year period, but a 13% sequential increase.

Liquid-based (Exo mdx) test volume of 13,578 compared to Select mdx volume of 4,455 for the same period last year.

“We expect our tissue growth rates to accelerate further throughout the second half of the year, driving a return to positive adjusted EBITDA as we exit 2026. These results underscore our track record of operating discipline and commercial execution. Combined with a strengthened balance sheet, we are well-positioned to drive sustainable revenue growth and profitability,” Michael McGarrity, CEO of mdxhealth, commented.

GPS PROMPT Results, AI Initiatives Support Growth

The company also said the recent peer-reviewed publication of the GPS PROMPT results from the Oxford study, alongside ongoing AI initiatives, provides compelling support for expanding market conversion and share gains in the active surveillance population ahead of the landmark PROTECT study.

As previously announced in the first-quarter update, the company made the strategic decision to discontinue the Resolve UTI offering to renew our focus on our core prostate cancer business.

The company completed this wind-down in Q2, with the permanent cessation of operations of our wholly-owned subsidiary Delta Laboratories and its Plano, Texas laboratory.

Gross profit increased 11% to $17.9 million compared to $16.1 million for the prior year.

The company eliminated the $10.4 million contingent liability to Novitas from its corporate structure and strengthened its balance sheet and cash position through a registered direct financing of $20 million.

MDxHealth Reaffirms 2026 Sales Guidance

MDxHealth reaffirmed its fiscal 2026 sales guidance of $110 million-$115 million compared to the consensus of $98.814 million.

The guidance reflects 20-26% growth over 2025 (excluding Resolve).

The company anticipates a recovery in the tissue-based business following the expected impact in the fourth quarter and first quarter post-integration and sales force restructuring from the ExoDx acquisition.

It delivered that recovery with a sequential increase of more than 1,400 tissue-based tests.

MDXH Price Action: MDxHealth shares were up 127.25% to $1.04 at the time of publication on Friday, according to Benzinga Pro data.

Image by Wasan Tita via Shutterstock